BioCentury
ARTICLE | Deals

Awaiting dialogue with FDA on GI program, microbiome play Finch looks to autism, HBV with new $90M round

September 17, 2020 3:22 PM UTC

With one pivotal readout in Clostridium difficile already achieved, microbiome company Finch has tapped investors for a $90 million series D round that will fund additional programs, and potentially help prepare it for a commercial rollout if FDA is quick to approve its lead candidate.

Finch Therapeutics Group Inc. CEO Mark Smith told BioCentury that although the company has been expecting that it would need to conduct a second pivotal trial of CP101 to prevent recurrence of C. difficile — a planned Phase III study that would start next half — there is still a chance FDA won’t even require the company to perform another trial...

BCIQ Company Profiles

Finch Therapeutics Group Inc.